Back

Crucell N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 11 may 2010 - 07:55
  • Statutory name Crucell N.V.
  • Title Crucell and NIH Announce Start of Malaria Vaccine Trial in Burkina Faso
  • Comments Leiden, the Netherlands (May 11, 2010) – Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced the start of a Phase I clinical study in Burkina Faso of its AdVac®-based malaria vaccine vector. Crucell is developing its malaria vaccine vector in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso, and the Noguchi Memorial Institute for Medical Research at the University of Ghana.

Related downloads

201005110000000008_2010 - 0511 Crucell and NIH Announce Start of Malaria Vaccine Trial in Burkina Faso.pdf

Date last update: 06 October 2022

Share information

Share on: Share this